FDA
-
-
-
-
-
-
-
Biogen earnings preview Q4: set for weaker print, Leqembi outlook in focus
-
-
-
-
-
-
-
FDA accepts LEQEMBI IQLIK application for weekly Alzheimer's treatment
-
-
-
-
-
-
-
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 America
-
-
-
-
-
-
-
Eisai completes FDA submission for LEQEMBI subcutaneous starting dose
-
-
-
-
-
-
-
Biogen completes acquisition of Alcyone Therapeutics
-
-
-
-
-
-
-
Eisai and Biogen launch at-home injection option for alzheimer's drug
-
-
-
-
-
-
-
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

